Citation Information :
Ramovecchi V, Franco F, Barbera GR. XEN Gel Staining with Trypan Blue: A Simple and Effective Technique to Improve Device Visualization during Implantation. J Curr Glaucoma Pract 2021; 15 (3):161-163.
The Xen Gel Stent (Allergan, Irvine, CA, USA) is a hydrophilic collagen-based gelatin tube of 6 mm in length which creates a channel of communication between the anterior chamber and the subconjunctival space allowing aqueous humor outflow. XEN is an ab interno, minimally invasive, glaucoma surgery device which has a better safety profile and offers a less invasive way of lowering intraocular pressure. Unfortunately, one of its weaknesses is that visualization of the implant during surgery is difficult, and this difficulty may be exacerbated, for instance, by a subconjunctival hemorrhage. The purpose of this paper is to describe a simple and effective technique for improving device visualization (XEN 45 μm) during the implantation.
Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014;121(11):2081–2090.
Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence: a cross sectional survey. Ophtalmology 2015;122(7):1308–1316.
Lemij HG, Hoevenaars JG, van der Windt C, et al. Patient satisfaction with glaucoma therapy: reality or myth? Clin Ophthalmol 2015;9:785–793.
Fernández S, Pardiñas N, Laliena JL, et al. Long-term tensional results after trabeculectomy. A comparative study among types of glaucoma and previous medical treatment. Arch Soc Esp Oftalmol 2009;84(7):345–352.
Ansari E. An update on implants for minimally invasive glaucoma surgery (MIGS). Ophthalmol Ther 2017;6(2):233–241.
Kerr NM, Wang J, Barton K. Minimally invasive glaucoma surgery as primary stand-alone surgery for glaucoma. Clin Exp Ophthalmol 2017;45(4):393–400.
Marcos Parra MT, Salinas López JA, López Grau NS, et al. XEN implant device versus trabeculectomy, either alone or in combination with phacoemulsification, in open-angle glaucoma patients. Graefes Arch Clin Exp Ophthalmol 2019;257(8):1741–1750.
Lavia C, Dallorto L, Maule M, et al. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: a systematic review and meta-analysis. PLoS One 2017;12(8):e0183142.
De Gregorio A, Pedrotti E, Stevan G, et al. XEN glaucoma treatment system in the management of refractory glaucomas: a short review on trial data and potential role in clinical practice. Clin Ophthalmol 2018;12:773–782.
Lewis R. Ab-interno approach to the subconjunctival space using a collage glaucoma stent. J cataract refract sur 2014;40: 1301–1306.
Hohberger B, Welge-Lüßen UC, Lämmer R. MIGS: therapeutic success of combined Xen gel stent implantation with cataract surgery. Graefes Arch Clin Exp Ophthalmol 2018;256(3): 621–625.
Gupta C, Mathews D. XEN® stent complications: a case series. BMC Ophthalmol 2019;19(1):253. DOI: 10.1186/s12886-019-1267-y.
Sng CCA, Chew PTK, Htoon HM, et al. Case series of combined XEN implantation and phacoemulsification in Chinese eyes: one-year outcomes. Adv Ther 2019;36(12):3519–3529.
Tsaousis KT, Kopsachilis N, Tsinopoulos IT, et al. Time-dependent morphological alterations and viability of cultured human trabecular cells after exposure to Trypan blue. Clin Exp Ophthalmol 2013;41:484–490.
Jhanji V, Chan E, Das S, et al. Trypan blue dye for anterior segment surgeries. Eye 2011;25:1113–1120.
Grover DS, Fellman RL. Confirming and establishing patency of glaucoma drainage devices using trypan blue. J Glaucoma 2013;22:e1–e2.
Rodrigues EB, Costa EF, Penha FM, et al. The use of vital dyes in ocular surgery. Surv Ophthalmol 2009;54(5):576–617.
Ferreira NP, Pinto JM, Teixeira F, et al. XEN gel stent early failure-dye-enhanced Ab-externo revision. J Curr Glaucoma Pract 2018;12(3):139–141.
